[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527892":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":22,"responsibleParty":88,"collaborators":7,"id":90,"slug":91,"hasResults":92,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":92,"sex":98,"minAge":99,"maxAge":7,"enrollmentInfo":100,"targetDuration":7,"studyType":103,"phases":7,"briefSummary":104,"conditions":105,"keywords":7,"overallStatus":39,"whyStopped":7,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Merit Medical Systems, Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DEVICE","Bearing nsPVA","Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Molly Ryan","CONTACT","314-620-7095","molly.ryan@merit.com",{"name":20,"role":16,"phone":7,"phoneExt":7,"email":21},"Vicky Brunk","vicky.brunk@merit.com",[23,37,56,71],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":7},"Astra Vascular\u002FAstra Vein Treatment Center","ACTIVE_NOT_RECRUITING","Brooklyn","New York","11234","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-73.94958,40.6501,{"lat":35,"lon":34},{"facility":38,"status":39,"city":40,"state":7,"zip":7,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":47,"contacts":48},"The Wesley Hospital","RECRUITING","Brisbane","Australia","AU",{"type":32,"coordinates":44},[45,46],153.02809,-27.46794,{"lat":46,"lon":45},[49,53],{"name":50,"role":16,"phone":51,"phoneExt":7,"email":52},"Sepinoud Firouzmand","0733719588","sepinoud.firouzmand@i-med.com.au",{"name":54,"role":55,"phone":7,"phoneExt":7,"email":7},"Nigel Mott, MD","PRINCIPAL_INVESTIGATOR",{"facility":57,"status":39,"city":58,"state":7,"zip":7,"country":41,"countryCode":42,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Alfred Health","Sydney",{"type":32,"coordinates":60},[61,62],151.20732,-33.86785,{"lat":62,"lon":61},[65,69],{"name":66,"role":16,"phone":67,"phoneExt":7,"email":68},"Adil Zia","61414063499","a.zia@alfred.org.au",{"name":70,"role":55,"phone":7,"phoneExt":7,"email":7},"Warren Clements, MD",{"facility":72,"status":39,"city":73,"state":7,"zip":7,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Royal Gwent Hospital (Aneurin Bevan UHB)","Newport","United Kingdom","UK",{"type":32,"coordinates":77},[78,79],-2.99835,51.58774,{"lat":79,"lon":78},[82,86],{"name":83,"role":16,"phone":84,"phoneExt":7,"email":85},"Judith Omang","01633 238084","Judith.Omang2@wales.nhs.uk",{"name":87,"role":55,"phone":7,"phoneExt":7,"email":7},"Nimit Goyal, MD",{"type":89,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100527892","bearing-nspva-embolization-for-uterine-artery-embolization-better-uae-100527892",false,"NCT06153667","Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)","Prospective, Multi-Center Study Using Bearing nsPVA Embolization Particles for the Treatment of uTErine fibRoids With Uterine Artery Embolization","BETTER-UAE","Inclusion Criteria:\n\n* Adult women ≥ 18 years old at the time of enrollment.\n* Subject has symptomatic uterine fibroid(s), suitable to embolization.\n* Subject provides written informed consent.\n\nExclusion Criteria:\n\n* Subject is pregnant.\n* Subject has suspected pelvic inflammatory disease or any other pelvic infection.\n* Subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).","FEMALE","18 Years",{"count":101,"type":102},100,"ESTIMATED","OBSERVATIONAL","This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.",[106],"Uterine Fibroid","2026-05-28",{"date":109,"type":110},"2026-05-29","ACTUAL",{"date":112,"type":110},"2024-08-22",{"date":114,"type":102},"2026-12",{"name":5,"class":6},4]